A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

June marks AML Awareness Month. It is a time to understand acute myeloid leukaemia. AML is a blood cancer needing quick ...

Early detection of blood cancer can be life-saving. Here are five warning signs you must never overlook, according to an ...